Moxibustion Not Superior to Other Therapies for Chemo-Induced Leukopenia
the Cancer Therapy Advisor take:
According to a new systematic review published in the journal Supportive Care in Cancer, researchers have found that moxibustion is not superior to other drug therapy for the treatment of patients with chemotherapy-induced leukopenia.
For the study, researchers analyzed 12 databases for randomized clinical trials that included moxibustion as the only treatment or as part of a regimen with standard therapy for the treatment of chemotherapy-induced leukopenia.
The researchers identified six randomized clinical trials that assessed a total of 681 patients with various types of cancer who were receiving chemotherapy or were receiving treatment post-chemotherapy. They determined that all of the studies identified were associated with a high risk of bias based on the Cochrane criteria.
Results showed that two of the six randomized clinical trials demonstrated moxibustion plus chemotherapy was more effective than chemotherapy alone. The other four trials found that moxibustion was more effective than standard drug therapy for chemotherapy-induced leukopenia. In addition, all six trials demonstrated that moxibustion was more effective than numerous types of control interventions for improving leukocyte count.
The findings suggest that moxibustion is not superior to other drug therapies for chemotherapy-induced leukopenia, but the authors note that they cannot draw firm conclusions due to the low number of studies included, the small sample size, and the poor methodological quality. Moxibustion is a traditional Chinese medicine made from dried mugwort.
Moxibustion not superior to other drug therapy for the treatment of chemotherapy-induced leukopenia
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models